Notalgia Paresthetica (NP) Case Study

Study Characteristics

Study Phase: II
Patient Population: 126 patients with Notalgia Paresthetica (NP) (Pruritus associated with NP)
IP Route of Administration: Systemic (oral)
Site Distribution: 33 sites (USA and Canada)
Study Procedures: Photographs, Pharmacokinetics, Electrocardiograms

Study Challenges and Solutions

Patient awareness: Challenge in advertisement as patients are often unaware of the name of their condition
Run-in period (screening): To ensure the enrollment of highly compliant patients and those with consistent itch
Patient compliance: Primary endpoints were relying on patient-reported assessments
Uncommon indication: PI with little experience in this indication

Study Highlights

Increased support for low-performing sites
Engaged with low-enrolling sites to ensure proper use of their local campaign budget
Creative advertising
Digital and local innovative marketing tactics to encourage patients to participate
Notalgia paresthetica cro specialty
Innovaderm managed 100% of the notalgia paresthetica studies (as per clinical trials.gov)
High compliance rate
Additional patient compensation for fully completed diary

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.

INNOVADERM CRO IS NOW INDERO.

Translation